Introduction
============

Dendritic cells (DCs) play a critical role in bridging the innate immune response with the adaptive immune system. DCs reside throughout the body, particularly enriched in secondary lymphoid organs (SLOs), intestinal lamina propria, and the epidermal layer of the skin, and they constantly sample antigen to maintain balance between immunity and tolerance. Infection triggers pattern recognition receptors (PRR) activation, promoting DC maturation, and the production of inflammatory cytokines including TNF-α, interleukin (IL)-1, IL-6, IL-12, and Type I interferons (IFN). Upon activation fully mature DCs migrate to SLOs where they interact with naive T cells, resulting in the activation of the adaptive immune response. DCs can be broadly categorized into conventional DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs are comprised of different subsets governed by differential expression of CD4 and CD8α (Villadangos and Schnorrer, [@B84]; Hashimoto et al., [@B38]). cDCs are highly efficient at presenting external antigens through the major histocompatibility complex (MHC) class I molecule to CD8+ T cells for the generation of cytotoxic T lymphocytes (CTLs), a process known as cross-presentation that plays an important role in pathological contexts including autoimmune disease, allograft rejection, and tumor immunity (Carbone and Bevan, [@B8]; Den Haan et al., [@B21]; Pooley et al., [@B65]). pDCs are also capable of capturing, processing, and presenting antigens to T cells (Sapoznikov et al., [@B68]; Young et al., [@B90]), but in comparison to cDCs, they possess more restricted antigen uptake and lower levels of co-stimulatory molecules and MHC (Colonna et al., [@B14]; Dalgaard et al., [@B17]; Young et al., [@B90]). Instead, pDCs patrol between blood vessels and the lymphatic system, and when they encounter viruses, they are capable of secreting very large amounts of Type I IFN in a short period of time as a strategy for viral control (Siegal, [@B75]; Colonna et al., [@B14]). Therefore, together cDCs and pDCs provide both distinct and overlapping contributions towards host defense against pathogens.

IFNs were first discovered to be an important anti-viral factor that interferes with viral replication in mammalian cells. There are three classes of IFN (Type I, II, and III) categorized based on their structural homology and the specific receptor with which they associate (Platanias, [@B63]). The Type I IFN family is very diverse and includes a single IFN-β member, numerous IFN-α variants (13 in human and 14 in mouse), and the lesser known IFN-ε, -κ, -ω, and -δ (Sen, [@B72]). Despite this diversity, all Type I IFNs bind exclusively to the interferon-α receptor (IFNAR). Upon receptor activation, IFNAR1 and IFNAR2 dimerize and phosphorylate the Janus Kinase family members TYK2 and JAK1. Activated TYK2 and JAK1 phosphorylate STAT1 and STAT2, and together they bind IRF9 to form a trimeric transcription factor, ISGF3. ISGF3 translocates into the nucleus and interacts with the ISRE elements to activate IFN-related gene transcription (Platanias, [@B63]). Type I IFNs are secreted by various cell types including fibroblasts, epithelial cells, innate immune cells, and lymphocytes, and they represent a key initiating factor against viral infections. In this review, we will describe the conventional mechanism of Type I IFN production by cDCs, and for brevity will restrict ourselves to virus infection scenarios. In addition, we will discuss a novel mechanism of Type I IFN induction that is triggered by tumor-necrosis factor receptor superfamily (TNFRSF) members such as TNFR-1 and lymphotoxin-β receptor (LTβR), independent of PRR activation. Finally, we will contextualize the versatile role of Type I IFN in tuning T cell responses in different contexts such as responses to replicating pathogens as opposed to cell-associated protein antigens.

PRR-Induced Type I IFN in Response to Viral Infection
=====================================================

Our immune system is in a constant evolutionary battle with pathogens that has played out through millennia. In order to combat viral infections, the immune system relies on detection tools, in particular PRR, that elicit potent Type I IFN expression.

Toll-like receptors
-------------------

Thus far, 13 mammalian TLRs have been identified (10 in human and 12 in mice) and each TLR recognizes a specific class of microbial pathogen-associated molecular patterns (PAMPs) that triggers distinct responses (Casanova et al., [@B10]). TLRs belong to the IL-1 receptor family, and all of them contain a common cytoplasmic domain referred to as the toll-interleukin-1 receptor (TIR) domain. Upon activation, the TIR domain recruits TIR-associated adapter molecules including MyD88, TRIF, TRAM, and TIRAP that mediate various downstream signaling pathways. TLRs are mainly expressed in immune cells such as neutrophils, macrophages, DC, and some lymphocytes, while non-immune cells such as fibroblasts and intestinal epithelial cells express a more restricted sets of TLRs (Reynolds et al., [@B66]; Akira, [@B3]). The majority of TLRs are found on the cell membrane with the exception of TLR3, 7--9, and 11--13, which are expressed within intracellular endosomes. These TLRs are associated with the detection of viral, bacterial, and parasitic nucleic acids (Meylan and Tschopp, [@B57]; Stetson and Medzhitov, [@B77]), and their sub-cellular compartmentalization allows the immune system to distinguish self from non-self antigens (Barton et al., [@B6]). Under certain circumstances however, host nucleic acids can be mistaken as non-self resulting in autoimmune diseases. For example, in the case of systemic lupus erythematosis, complexes of autoreactive antibodies and host nucleic acids can trigger the activation of endosomal TLRs in pDCs, resulting in uncontrolled production of Type I IFN and disease pathology (Elkon and Stone, [@B25]).

Conventional DCs and pDCs express different sets of TLRs that facilitate their specialized function. Human pDCs lack TLR3 but express high levels of TLR7, TLR8, and TLR9, and they are responsible for the production of large amounts of Type I IFN in response to viral infections (Hornung et al., [@B40]). The signaling pathway downstream of TLR7, 8, and 9 is mediated through the key adaptor molecule MyD88 (Takeda and Akira, [@B79]). Upon activation, MyD88 recruits IRAK4 and IRAK1 to the receptors, and through interaction of their death domains, IRAK1 becomes phosphorylated. Activated IRAK1 further recruits and activates the constitutively expressed IRF7 in pDC, resulting in the production of Type I IFN (Coccia et al., [@B13]; Asselin-Paturel and Trinchieri, [@B4]; Honda et al., [@B39]).

In contrast to pDCs, the role of TLR7 and TLR8 in cDCs predominantly initiates a DC maturation program that leads to the production of IL-12 rather than Type I IFN (Ito, [@B41]; Larangé et al., [@B48]). Type I IFN production by cDC is primarily triggered through the activation of TLR3 that recognizes viral-derived double stranded RNA and TLR4 that recognizes the gram negative bacterial cell wall component lipopolysaccharide. TLR3 is the only TLR that exclusively recruits Trif to mediate signaling, while TLR4 signals through both MyD88 and Trif (Weighardt et al., [@B86]). Trif is the key adaptor molecule that mediates Type I IFN expression downstream of both receptors, and upon activation, Trif binds the TNF receptor-associated factor 3 (TRAF3) and TRAF6, which recruits RIP1 that induces NFκB activation. Conversely, TRAF3 becomes polyubiquitinated to the lysine at position 63 of the ubiquitin molecule (K63-linkage). K63-linked TRAF3 is essential for the recruitment of TBK1, IKKε, and IRF3, ultimately leading to IRF3 phosphorylation (Oganesyan et al., [@B61]; Tseng et al., [@B81]; Häcker et al., [@B36]). Phoshporylated IRF3 subsequently homo-dimerizes and translocates into the nucleus. Together IRF3 and NFκB form the transcription factors required for the expression of IFN genes (Figure [1](#F1){ref-type="fig"}). Taken together, pDCs and cDCs have unique roles in response to infection. The expression of different PRRs and differences in the signaling that mediate Type I IFN production in pDCs versus cDCs conspire to contain infection by triggering a systemic antiviral state and efficiently priming T cell activation.

![**Induction of Type I IFN by PRR during a viral infection**. TLR3, 7, and 9 are mainly expressed within the endosomes of innate immune cells. Virus or virus-infected cells are taken up by macrophages or DCs, and the viral nucleic molecules are exposed upon endosomal acidification. Activation of TLR7 and 9 requires signaling through MyD88 and recruitment of IRAK4, IRAK1, and IRF7. IRF7 becomes phosphorylated and translocates into the nucleus upon dimerization resulting in transcription of Type I IFN genes. TLR3 signals exclusively through Trif which binds TRAF6 and recruits RIP1 for NF-κB activation. Trif also binds TRAF3 leading to TRAF3 K63-linked ubiquintination, facilitating the recruitment of TBK1, IKKε and IRF3 for IRF3 phosphorylation. Phosphorylated IRF3 homo-dimerizes and translocates into the nucleus for transcription of Type I IFN genes. RIG-I or RIG-I like receptors are expressed in all nucleated cells, and they recognizes viral RNA found in the cytoplasm. Upon activation, RIG-I recruits MAVS through the CARD domain interaction, and, analogous to TRIF, MAVS further binds IKKε, TBK1 and IRF3 to promote IRF3-activation and Type I IFN expression.](fimmu-04-00094-g001){#F1}

RIG-I or RIG-I like receptors
-----------------------------

In contrast to TLRs which are primarily expressed on innate immune cells, RIG-I are ubiquitously expressed in the cytoplasm of all nucleated cells. Instead of actively sensing viral particles, RIG-I are triggered when cells become infected. RIG-I and the RIG-I like receptors, such as the melanoma differentiation antigen 5 (MDA5) belong to a family of DExD/H box RNA helicases. The N-terminal region of RIG-I is characterized by two caspase recruitment domains (CARD), and the C-terminal region contains RNA helicase activity (Yoneyama and Fujita, [@B89]). RIG-I recognizes double stranded RNA by the RNA helicase domain, and through a CARD--CARD interaction, RIG-I recruits the CARD-containing adaptor MAVS (also known as VISA, IPS-1, or CARDIF) to mediate downstream events (Yoneyama and Fujita, [@B89]). Upon activation, MAVS localizes on sub-cellular compartments including the mitochondrial membrane and peroxisomes. Signaling through the peroxisomal-localized MAVS leads to rapid induction of antiviral genes but independent of Type I IFN production (Dixit et al., [@B24]). In contrast, mitochondrial MAVS produces a slower kinetic that results in Type I IFN expression. Using the mitochondria membrane as a scaffold and powered by the mitochondrial membrane potential (Koshiba et al., [@B46]), MAVS interacts with TRAF3, TBK1, and IKKε to form a "signalosome" that phosphorylates IRF3 and IRF7 for Type I IFN production (Kawai et al., [@B45]; Seth et al., [@B73]). *In vivo* models have shown that RIG-I-deficient mice, despite having intact TLR signaling, succumb to infection by vesicular stomatitis virus, Newcastle disease virus, and Sendai virus (Kato et al., [@B44]). TLRs and RIG-I signaling complement each other to provide complete coverage across various types of viruses, and both detection systems are geared toward rapid production of Type I IFN that leads to a systemic antiviral state and the control of viral infection.

Induction of Type I IFN by the TNFR Family
==========================================

The TNFRSF is a very diverse family of receptors comprising of 29 different family members that provide critical signals regulating numerous physiological functions including inflammation, lymphoid organ development, and adaptive immune responses (Force et al., [@B28]; Sarin et al., [@B69]; Lin and Stavnezer, [@B53]). More recently, it has been shown that TNFR-1 and LTβR activation can trigger Type I IFN expression in macrophages and in cDCs respectively (Yarilina et al., [@B88]; Summers-deLuca et al., [@B20]). The production of Type I IFN by TNFR family members in the absence of PRR signaling signifies a novel mechanism of Type I IFN induction that may be critical during immune responses to non-replicating antigen such as tumor antigens and self-antigens.

TNFR-1 and Type I IFN
---------------------

TNF-α was first discovered to be an endotoxin-induced serum factor that exerts cytotoxic effects against sarcoma cells in mice (Carswell et al., [@B9]), and it has since been recognized as a pleiotropic cytokine that regulates numerous biological functions. Macrophages are major producers of TNF-α in both acute immune responses and chronic inflammatory diseases. TNF-α induces inflammation by affecting many different cell types throughout the body due to the ubiquitous expression of two distinct receptors, TNFR-1 and TNFR-2. Most biological functions are mediated through TNFR-1, while TNFR-2 has been shown to potentiate TNFR-1 induced cell death (Li et al., [@B52]). TNF-α stimulation in primary human and mouse macrophages induces the phosphorylation of IRF1 and IRF3 leading to the production of Type I IFN and the secretion of chemokines, such as CXCL10 and CXCL11 (Yarilina et al., [@B88]). Activated T cells express the chemokine receptor CXCR3 that binds to CXCL9, CXCL10, and CXCL11, resulting in their recruitment into sites of inflammation, and numerous studies have recognized the critical role of CXCR3 activating chemokines in various immune responses such as autoimmune mediated skin inflammation and allograft rejection that lack overt PRR activation (Flier et al., [@B27]; Meyer et al., [@B56]; Zhao et al., [@B91]). What is important to note is that the modest and gradual kinetics of the TNFR-1 induced Type I IFN response described above contrast with the more rapid and robust Type I IFN induced by PRR mediated responses such as what occurs during infection -- see Figure [2](#F2){ref-type="fig"} (Sakaguchi et al., [@B67]; Honda et al., [@B39]; Seth et al., [@B73]).

![**Type I IFN promotes T cell priming during viral infection versus soluble antigens**. **(A)** Viruses can trigger PRR activation on immature DCs, leading to DC maturation and production of various pro-inflammatory cytokines and a large quantity of Type I IFN. In this scenario, DCs are strongly activated, and they are capable of directly interacting with CD8+ T cells for the generation of virus-specific CTLs. In the case of soluble antigens, DCs are poorly activated due to the absence of PRR-stimulus. Semi-mature DCs must first interact with helper CD4+ helper T cells which rapidly up-regulate "help signals" CD40L and LTαβ upon activation. DC-intrinsic LTβR and CD40 activation promotes DC maturation, with LTβR signaling producing a modest amount of Type I IFN for a sustained period that facilitates CD8+ T cell expansion. **(B)** The differences in kinetics and magnitude of Type I IFN induced by PRR or TNFSFR are illustrated graphically here.](fimmu-04-00094-g002){#F2}

LTβR and Type I IFN
-------------------

LTβR is expressed on stromal cells, DCs, macrophages, and high endothelial venules, while the ligand LTαβ is found on lymphoid tissue inducer cells, B cells and activated T cells. LTβR signaling in stromal cells is required for the development of SLOs (Murphy et al., [@B58]; Mebius, [@B55]), and it also plays an important role in the homeostatic maintenance of specific subsets of cDCs in the spleen (Kabashima et al., [@B42]; Wang et al., [@B85]; De Trez et al., [@B18]). More recently, our lab as well as others have examined the role of LTβR in DC: T cell cross-talk (Summers-DeLuca et al., [@B78]; León et al., [@B51]). During an immune response, activated CD4+ helper T cells up-regulate CD40L and LTαβ which binds to the corresponding receptors CD40 and LTβR respectively on cDCs. Both CD40 and LTβR signaling provide "help" for cDCs so that they may optimally cross-present antigen for CD8+ T cell activation. Using an immunization model of cell-associated protein antigen, we found that LTβR signaling in cDCs is required for optimal CD8+ T cell clonal expansion while CD40 signaling was required for CD8+ T cell effector functions. Since Benedict and colleagues demonstrated that LTβR signaling could induce Type I IFN in stromal cells, independent of PRR activation (Schneider et al., [@B71]), we also explored whether direct LTβR stimulation leads to Type I IFN induction in DCs. We found that, not unlike the scenario for TNFR-1, LTβR stimulation induced a modest level of Type I IFN that gradually increased over time. Furthermore, LTβR signaling was required for maximal Type I IFN production in the context of LPS (TLR4) co-stimulation (Summers-deLuca et al., [@B20]).

Interestingly, the modest level of Type I IFN induced by LTβR signaling in cDCs was important for optimizing CD8+ T cell clonal expansion *in vitro*, since low amounts of exogenous IFN-α can rescue CD8+ T cell expansion in the absence of LTβR signaling. Hence, Type I IFN produced by LTβR or TNFR-1 may facilitate optimal T cell recruitment and/or clonal expansion (Figure [2](#F2){ref-type="fig"}). Given that some autoimmune diseases are characterized by a "Type I IFN signature" (Lande et al., [@B47]; Sozzani et al., [@B76]; Elkon and Stone, [@B25]), it will be of interest to determine the relevancy of these PRR-independent signals for the induction of Type I IFN in the context of autoimmunity.

The Many Roles of Type I IFN
============================

Thus far, we have described two very different mechanisms for Type I IFN induction in DCs and monocytes. PRRs detect viral nucleic acids, to produce a robust Type I IFN response for viral clearance, and this is particularly the case for pDCs. Conversely, TNFRSF (TNFR-I, LTβR) induce a modest but prolonged expression of Type I IFN that acts in a co-stimulatory manner to potentiate T cell-mediated immunity (Figure [2](#F2){ref-type="fig"}B). Therefore, the difference in level, period, and duration of Type I IFN produced by DCs likely dictate the pleiotropic effects of this cytokine resulting in pro-inflammatory or pro-regulatory immune functions.

Pro-inflammatory function of Type I IFN
---------------------------------------

Type I IFN is generally regarded as a pro-inflammatory cytokine in numerous immune settings such as autoimmune diseases like psoriasis and systemic lupus erythematosus (Nestle et al., [@B59]; Lande et al., [@B47]; Elkon and Stone, [@B25]), allograft rejection in transplantation (Tovey et al., [@B80]), and immunity against tumors (Diamond et al., [@B22]; Fuertes et al., [@B29]). Type I IFN has robust pro-inflammatory effects that can act in both an autocrine and paracrine manner on immune cells to modulate their functions. During an immune response with minimal PRR activation, DCs cannot reach maximal immunogenic status, and Type I IFN overcomes this hurdle by promoting DC maturation (Le Bon and Tough, [@B50]; Longhi et al., [@B54]; Axtell et al., [@B5]). IFNAR activation in DC triggers NFκB and p38 mitogen-activated protein kinase (MAPK) activation, resulting in the up-regulation of MHC class I and class II as well as co-stimulatory molecules B7-H1 and B7-H2 (Pollara et al., [@B64]). In addition, blood circulating monocytes, when differentiated into DCs in the presence of Type I IFN, upregulate the chemokine receptor CCR7 thus allowing them to migrate more efficiently into SLOs (Parlato, [@B62]). In human CD4+ T cells, Type I IFN can complement IL-12 to drive TH-1 differentiation, where IFNAR-mediated STAT2 phosphorylation recruits and activates STAT4, a transcription factor that potentiates IL-12R signaling (Farrar et al., [@B26]; Gautier et al., [@B32]). Moreover, Type I IFN signaling through STAT4 has also been implicated in the induction of IFN-γ in natural killer cells and T cells, particularly in the absence of STAT1 (Nguyen et al., [@B60]). Various studies have reported that Type I IFN acts as a potent third signal that promotes antigen cross-priming (Curtsinger et al., [@B16]; Le Bon et al., [@B49]; Le Bon and Tough, [@B50]). IFNAR activation in CD8+ T cell can induce chromatin remodeling through histone acetelyation, promoting transcription of many genes required for clonal expansion and production of effector molecules (Agarwal et al., [@B2]). Lastly, Type I IFN prolongs the CD8+ T cell expansion phase in response to cross-presented antigen, and it enhances the responsiveness of antigen specific CD8+ T cells to IL-2 and IL-15 for increased survival (Le Bon et al., [@B49]). Hence, Type I IFN can independently act on DCs, CD4+ T cells, and CD8+ T cells through very different mechanisms that facilitate inflammatory immune responses.

Anti-inflammatory role of Type I IFN
------------------------------------

Many experimental and clinical settings use Type I IFN as a treatment to quiet inflammatory conditions, suggesting that Type I IFN can exert immunoregulatory functions. In particular, IFN-β has been shown to be an effective therapeutic treatment for collagen-induced arthritis (Van Holten et al., [@B83]; Adriaansen et al., [@B1]), relapsing-remitting multiple sclerosis (MS) (Weinstock-Guttman et al., [@B87]) and autoimmune familial Mediterranean fever (Tweezer-Zaks et al., [@B82]; Guarda et al., [@B35]). The anti-inflammatory functions of Type I IFN, particularly in MS, have been characterized by numerous studies, and yet the exact mechanism remains unclear. Blood-derived DCs become activated upon IFNAR activation, however astrocytes and microglia in the central nervous system (CNS) down-regulate MHC-II in response to Type I IFN (Satoh et al., [@B70]; Hall et al., [@B37]). T cell recruitment into the CNS may require Type I IFN to induce relevant CXCR3 attracting chemokines, however other studies have also showed that prolonged IFN-β treatment in MS patients down-regulates the expression of cell adhesion molecules such as VCAM-1 and ICAM-1 in brain endothelial cells, resulting in reduced immune cell infiltration into the CNS (Corsini et al., [@B15]; Defazio et al., [@B19]). In addition, IFN-β can prevent leukocyte egress from lymph nodes by down-regulating the sphingosine 1-phosphate receptor-1 (S1P1) (Shiow et al., [@B74]; Gao et al., [@B31]), and S1P receptor agonists are used to treat MS (Kataoka et al., [@B43]; Chun and Hartung, [@B12]; Choi et al., [@B11]; Galicia-Rosas et al., [@B30]). IFN-β or IFNAR1 deficient mice have been shown to produce an enhanced number of antigen specific CD8+ T cells when immunized with a DNA-based vaccine, suggesting that Type I IFN is also required to control T cell proliferation (Dikopoulos et al., [@B23]). Recent studies showed that IFN-induced STAT1 activation negatively regulates the expression and function of the oncogene c-myc in CD8+ T cells which is important for homeostatic proliferation (Gil et al., [@B33], [@B34]). Furthermore, other studies have also shown that IFNAR or IFN-β deficient mice exhibit lower numbers of IL-10 producing T cells, which may also explain the increased CD8 T cell expansion in the absence of IFNAR signaling (Dikopoulos et al., [@B23]; Bochtler et al., [@B7]). It is important to point out, however, that scenarios where IFNAR signaling is completely absent may lead to different effects on shaping T cell responses than situations where the levels/kinetics of Type I IFN production have been altered.

Conclusions
===========

Type I IFN is a pleiotropic cytokine that affects many different cell types with a wide range of effects. The modulation of the innate and adaptive immune responses relies on a finely tuned rheostat of Type I IFN production. The amount of IFN produced through a particular time frame during the course of an immune reaction will likely dictate very different outcomes. Therefore, understanding the mechanisms underlying Type I IFN induction by DCs is crucial for providing future groundwork in developing therapeutics that quiet autoimmunity or promote pathogen and tumour clearance.
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